Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bstrazumab
- Development stage
- Preclinical
- Lead developer
- Curemeta
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CM-14 (bstrazumab) is a preclinical-stage antibody-drug conjugate (ADC) developed by Curemeta for the treatment of solid tumors, including metastatic colon, gastric, and pancreatic cancers. It consists of a humanized IgG1 monoclonal antibody targeting the oncofetal antigen TRA-1-60 (an epitope on podocalyxin-like protein 1), conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE) via a cathepsin-cleavable valine-citrulline dipeptide linker. By targeting TRA-1-60, which is expressed on pluripotent stem cells and various cancer cells but absent in most normal adult tissues, CM-14 aims to selectively deliver cytotoxic payloads to tumor cells. It is the humanized successor to the chimeric antibody CM-09.
- Other names
- Bstrazumab
02
Targets
TUBB (Tubulin (alpha and beta subunits))Podocalyxin-like protein 1 (TRA-1-60 epitope)
Beyond the preview
Go deeper on bstrazumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bstrazumab.